Minesh Rajpal, MD
Nephrology · Peoria, AZNPI 1568760502
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $290,714 of the $402,962 with a category attached, or 72.1%. It is spread thinly across 31 manufacturers, the largest accounting for just 22.3%. Among nephrology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 692 payments — averaging $582.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$90K
- Bayer$69K
- Amgen$62K
- Boehringer Ingelheim$46K
- Akebia Therapeutics Inc$37K
- Lilly USA, LLC$32K
- plus $66K from 25 others
Across 85 payments — averaging $37,541 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.7M
- AstraZeneca$778K
- Boehringer Ingelheim Pharma GmbH & Co.kg$240K
- Boehringer Ingelheim International GmbH$200K
- Bayer$196K
- Vertex$36K
- plus $31K from 2 others
What the payments were for
- Consulting fees$57,38214%
- Speaking & faculty fees$290,71472%
- Travel & lodging$37,4969%
- Food & beverage$17,1934%
- Education$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 172 | $89,706 |
| Bayer | 97 | $68,834 |
| Amgen(2 entities) | 113 | $62,312 |
| Boehringer Ingelheim | 45 | $46,289 |
| Akebia Therapeutics Inc | 69 | $37,230 |
| Lilly USA, LLC | 27 | $32,094 |
| GSK | 35 | $29,324 |
| Travere Therapeutics, Inc. | 38 | $14,361 |
| Sobi, Inc | 6 | $5,542 |
| Idorsia Pharmaceuticals US Inc | 7 | $4,618 |
| Calliditas Therapeutics US Inc. | 7 | $4,576 |
| Astrazeneca UK Limited | 2 | $3,617 |
| Aurinia Pharma U.S., Inc. | 8 | $2,856 |
| Otsuka America Pharmaceutical, Inc. | 17 | $365 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $184 |
| OPKO Pharmaceuticals, LLC | 8 | $154 |
| Novo Nordisk | 7 | $153 |
| Vantive US Healthcare LLC | 1 | $128 |
| Nxstage Medical, Inc. | 1 | $119 |
| Mallinckrodt Hospital Products Inc. | 4 | $85 |
| Veloxis Pharmaceuticals, Inc. | 3 | $65 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Novartis | 3 | $63 |
| Scpharmaceuticals Inc. | 2 | $50 |
| Vifor Pharma, Inc. | 2 | $37 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $33 |
| Apellis Pharmaceuticals, Inc. | 2 | $32 |
| Ardelyx, Inc. | 1 | $23 |
| Sanofi | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$402,962 in reported general payments places this provider in the 95th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 1,068 | $1,231,243 |
| KrystexxaPegloticase | 13 | $954,580 |
| KerendiaFinerenone | 344 | $396,135 |
| JardianceEmpagliflozin | 211 | $233,025 |
| LokelmaSodium Zirconium Cyclosilicate | 57 | $59,433 |
| DapagliflozinDapagliflozin Propanediol | 53 | $30,448 |
| InvokanaCanagliflozin | 14 | $17,294 |
| MyrbetriqMirabegron | 24 | $14,631 |
| Fluconazole | 181 | $8,369 |
| Tacrolimus | 68 | $6,578 |
| Potassium Citrate ErPotassium Citrate | 66 | $5,803 |
| Cinacalcet Hcl | 16 | $5,328 |
| Calcitriol | 166 | $5,113 |
| Methenamine Hippurate | 38 | $5,012 |
| Losartan Potassium | 451 | $4,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $89,706 | $1,290,6761,125 claims |
| AmgenKrystexxa | $62,312 | $954,58013 claims |
| BayerKerendia | $68,834 | $396,135344 claims |
| Boehringer IngelheimJardiance | $46,289 | $233,025211 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $17 | $1,92140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 nephrology providers in Arizona.
Other nephrology in Peoria
- Randy CooperPeoria$597K
- Umar WaheedPeoria$150K
- Amer KhanPeoria$71K
- Asan AriffPeoria$5K
- Samer Bani HaniPhoenix$54K
- Aneesha ShettyTucson$34K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
- Saeed ShaffiScottsdale$19K
- Jean RobeySun City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.